EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

@article{Smolen2017EULARRF,
  title={EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update},
  author={Josef S. Smolen and Robert B M Landew{\'e} and Johannes W J Bijlsma and Gerd R{\"u}diger Burmester and Katerina Chatzidionysiou and Maxime Dougados and Jackie Nam and Sofia Ramiro and Marieke Voshaar and Ronald F. van Vollenhoven and Daniel Aletaha and Martin Aringer and Maarten Boers and Christopher D. Buckley and Frank Buttgereit and Vivian P. Bykerk and Mario Humberto Cardiel and Bernard Combe and Maurizio Cutolo and Yvonne van Eijk-Hustings and Paul Emery and Axel Finckh and Cem Gabay and Juan Jos{\'e} G{\'o}mez-Reino and Laure Gossec and Jacques-Eric Gottenberg and Johanna Maria Wilhelmina Hazes and Thomas W J Huizinga and Meghna Jani and Dmitry E Karateev and Marios Kouloumas and Tore K. Kvien and Zhanguo Li and Xavier Mariette and Iain B. McInnes and Eduardo Mysler and Peter Nash and Karel Pavelka and Gyula Po{\'o}r and Christophe Richez and Piet L.C.M. van Riel and Andrea Rubbert-Roth and Kenneth G. Saag and Jos{\'e} Ant{\'o}nio Pereira da Silva and Tanja Alexandra Stamm and Tsutomu Takeuchi and Ren{\'e} Westhovens and Maarten P T de Wit and D{\'e}sir{\'e}e Mfm van der Heijde},
  journal={Annals of the Rheumatic Diseases},
  year={2017},
  volume={76},
  pages={960 - 977}
}
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. [] Key Method Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
TLDR
These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
TLDR
This systematic literature review consistently confirmed the previously reported efficacy of bDMARDs in RA and provided additional information on b DMARD switching and dose reduction.
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
TLDR
This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR’s RA management recommendation.
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
TLDR
Addition of GCs to csDMARD therapy may be beneficial but the benefits should be balanced against the risk of toxicity, and tofacitinib and baricitinib are efficacious in patients with RA, including those with refractory disease.
Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
TLDR
The therapy with different bDMARDs added to a csDMARD led to very similar results – a minimal disease activity and a state of remission in the GOL treatment group only as per DAS28-CRP.
Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
TLDR
There is an increasing evidence of the potential of some bDMARDs and ts DMARDs in monotherapy, which may become a considerable and realistic option in RA patients.
2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?
TLDR
It is disappointed to note that the updated guidelines recommend the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) or targeted synthetic DMARDs (tsDMARDS) immediately following failure of monotherapy with conventional synthetic DMARDSs (csDMARD) in those patients with poor prognostic factors.
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
TLDR
Abatacept in combination with non-MTX csDMARDs is clinically effective and well tolerated in patients with moderate-to-severe RA, providing similar benefits to those seen with abatACEpt plus MTX.
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
TLDR
Examination of prescribing patterns and reasons for current RA treatment practice in Europe and Japan found TNFis were the most commonly prescribed targeted therapy at first-line, and TNFi cyclers had longer time from diagnosis to second-line targeted therapy initiation than MOA switchers.
...
...

References

SHOWING 1-10 OF 439 REFERENCES
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
TLDR
There is good evidence for the efficacy of biological agents in patients with RA and safety data confirm an increased risk of bacterial infection and TB with TNFi compared with conventional DMARDs.
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
TLDR
The systematic literature review confirms efficacy of biological DMARDs in RA and addresses different treatment strategies with the potential for reduction in therapy, particularly with early disease control, and highlights emerging therapies.
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
TLDR
The findings from this SLR confirm the known safety pattern of s DMARDs and bDMARDs for the treatment of RA.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
TLDR
The 2010 European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and b DMARDs, respectively) have been updated and are intended to improve outcome in patients with RA.
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
TLDR
The proposed nomenclature may provide means to group and distinguish the different types of DMARDs in clinical studies and review articles.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
TLDR
Recommendations are intended to inform rheumatologists, patients and other stakeholders about a European consensus on the management of RA with DMARDs and GCs as well as strategies to reach optimal outcomes of RA based on evidence and expert opinion.
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
TLDR
A comparison with other synthetic DMARDs was in favour of MTX, though at the tested doses MTX and leflunomide were equally effective, and MTX was well-tolerated and effective in reducing signs and symptoms, disability and structural damage.
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
TLDR
Considering the limitations of an open-label study, adalimumab alone or in combination with standard DMARDs appeared to be well tolerated and effective in 6610 difficult-to-treat patients with active RA treated in clinical practice.
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
TLDR
Addition of low-dose glucocorticoids to csDMARD therapy produces benefits in early RA, confirming that initial treatment of RA with low- dose prednisone plus methotrexate (MTX) results in better clinical and structural outcomes than treatment with MTX alone.
Ef fi cacy of conventional synthetic disease-modifying antirheumatic drugs , glucocorticoids and tofacitinib : a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
TLDR
Addition of low-dose glucocorticoids to csDMARD therapy produces benefits in early RA, confirming that initial treatment of RA with lowdose prednisone plus methotrexate (MTX) results in better clinical and structural outcomes than treatment with MTX alone.
...
...